Show simple item record

FieldValueLanguage
dc.contributor.authorChow, Michael Y.T.en
dc.contributor.authorQiu, Yingshanen
dc.contributor.authorLam, Jenny K.W.en
dc.date.accessioned2020-09-14
dc.date.available2020-09-14
dc.date.issued2020en
dc.identifier.urihttps://hdl.handle.net/2123/23304
dc.description.abstractRNA-based medicine is receiving growing attention for its diverse roles and potential therapeutic capacity. The largest obstacle in its clinical translation remains identifying a safe and effective delivery system. Studies investigating RNA therapeutics in pulmonary diseases have rapidly expanded and drug administration by inhalation allows the direct delivery of RNA therapeutics to the target site of action while minimizing systemic exposure. In this review, we highlight recent developments in pulmonary RNA delivery systems with the use of nonviral vectors. We also discuss the major knowledge gaps that require thorough investigation and provide insights that will help advance this exciting field towards the bedside.en
dc.language.isoenen
dc.rightsOther
dc.subjectCOVID-19en
dc.subjectCoronavirusen
dc.titleInhaled RNA Therapy: From Promise to Realityen
dc.typeArticleen
dc.identifier.doi10.1016/j.tips.2020.08.002
dc.relation.otherUniversity Grants Committeeen
usyd.facultyFaculty of Medicine and Health, Sydney Medical Schoolen


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.